230 related articles for article (PubMed ID: 32041867)
21. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
22. c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.
Musso L; Mazzini S; Rossini A; Castagnoli L; Scaglioni L; Artali R; Di Nicola M; Zunino F; Dallavalle S
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):615-629. PubMed ID: 29229300
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent.
Murugavel S; Ravikumar C; Jaabil G; Alagusundaram P
Comput Biol Chem; 2019 Apr; 79():73-82. PubMed ID: 30731361
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
[TBL] [Abstract][Full Text] [Related]
25. Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
Jain N; Zhu H; Khashab T; Ye Q; George B; Mathur R; Singh RK; Berkova Z; Wise JF; Braun FK; Wang X; Patel K; Xu-Monette ZY; Courty J; Young KH; Sehgal L; Samaniego F
Leukemia; 2018 Mar; 32(3):663-674. PubMed ID: 28690315
[TBL] [Abstract][Full Text] [Related]
26. The Aza-Analogous Benzo[
Aichinger G; Lichtenberger FB; Steinhauer TN; Flörkemeier I; Del Favero G; Clement B; Marko D
Molecules; 2020 Mar; 25(7):. PubMed ID: 32230817
[TBL] [Abstract][Full Text] [Related]
27. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells.
Negi SS; Brown P
Oncotarget; 2015 Oct; 6(33):34846-58. PubMed ID: 26472108
[TBL] [Abstract][Full Text] [Related]
28. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
29. A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.
Blower TR; Bandak A; Lee ASY; Austin CA; Nitiss JL; Berger JM
Nucleic Acids Res; 2019 Sep; 47(15):8163-8179. PubMed ID: 31287876
[TBL] [Abstract][Full Text] [Related]
30. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
[TBL] [Abstract][Full Text] [Related]
31. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Stahl M; Kasimir-Bauer S; Harstrick A
Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
[TBL] [Abstract][Full Text] [Related]
33. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
34. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Walsby EJ; Coles SJ; Knapper S; Burnett AK
Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
[TBL] [Abstract][Full Text] [Related]
35. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
36. Identification of topoisomerases as molecular targets of cytosporolide C and its analog.
Otake K; Yamada K; Miura K; Sasazawa Y; Miyazaki S; Niwa Y; Ogura A; Takao KI; Simizu S
Bioorg Med Chem; 2019 Aug; 27(15):3334-3338. PubMed ID: 31204230
[TBL] [Abstract][Full Text] [Related]
37. 3,7-bis-benzylidene hydrazide ciprofloxacin derivatives as promising antiproliferative dual TOP I & TOP II isomerases inhibitors.
Samir M; Ramadan M; Abdelrahman MH; Abdelbaset MS; Abourehab MAS; Abdel-Aziz M; Abuo-Rahma GEA
Bioorg Chem; 2021 May; 110():104698. PubMed ID: 33676043
[TBL] [Abstract][Full Text] [Related]
38. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.
Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ
Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045
[TBL] [Abstract][Full Text] [Related]
39. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Cancer Discov; 2019 Aug; 9(8):1036-1049. PubMed ID: 31092402
[TBL] [Abstract][Full Text] [Related]
40. Phytochemical naphtho[1,2-b] furan-4,5‑dione induced topoisomerase II-mediated DNA damage response in human non-small-cell lung cancer.
Chien CM; Yang JC; Wu PH; Wu CY; Chen GY; Wu YC; Chou CK; Tseng CH; Chen YL; Wang LF; Chiu CC
Phytomedicine; 2019 Feb; 54():109-119. PubMed ID: 30668360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
